EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detection of Islet Autoantibodies in Whole Blood by Antibody Detection by Agglutination-PCR (ADAP) Technology Is Sensitive and Suitable for General Population Screening Programs

Tal Oron iD, Felipe de Jesus Cortez, Biana Shtaif, Peter V Robinson, Michal Yackobovitch-Gavan, Devangkumar Tandel, David Seftel, Moshe Phillip iD, Cheng-Ting Tsai, Galia Gat-Yablonski iD

Pediatric Diabetes · 2024

DOI: 10.1155/2024/4238394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Diabetes, 2024. Verfasst von Tal Oron und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center…. Hauptthemen laut MEDLINE: Autoantibodies, Diabetes Mellitus, Type 1, Islets of Langerhans, Mass Screening. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Enable Biosciences Inc., Schneider Children’s Medical Center of Israel, JDRF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Detection of type 1 diabetes (T1D) at the preclinical stage is possible by detecting islet autoantibodies (IAs) years before the appearance of symptomatic diabetes. The Antibody Detection Israeli Research is a general population screening program searching for children with multiple IAs who are at risk of developing T1D. IAs are measured in capillary or venous whole blood (WB) samples using the novel ultrasensitive antibody detection by agglutination-PCR (ADAP) technology.

Objective

To assess the accuracy and reliability of the ADAP assay in venous and capillary WB. Materials and Methods. In total, 50 children with T1D and 50 healthy controls participated in the study. Venous and capillary blood samples were drawn from participants with T1D, while only venous blood was drawn from the controls. The ADAP assay in venous and capillary blood was compared to the currently used assays in their ability to detect glutamic acid decarboxylase (GADA), islet antigen-2 (IA-2A), and insulin autoantibodies (IAAs).

Results

The area under the curve using the receiver operating characteristic curves was comparable between the ADAP assay in WB and standard enzyme-linked immunosorbent assay (ELISA)/radioimmunoassay (RIA) for all three IAs GADA 0.946 (95% CI: 0.900–0.991) vs. 0.949 (0.906–0.992), P = 0.873 ; IA-2A 0.747 (0.649–0.844) vs. 0.666 (0.587–0.744), P = 0.106 ; IAA 1.000 (1.000–1.000) vs. 1.000 (1.000–1.000), P = 1.000 . The correlation between the levels of IA in venous and capillary WB using ADAP was R2 = 0.958 ( P < 0.01 ), R2 = 0.943 ( P < 0.01 ), and R2 = 0.711 ( P < 0.01 ) for GADA, IA-2A, and IAA, respectively. IA levels in venous and capillary WB using ADAP were comparable without a proportional bias in Bland–Altman’s plots of agreement, suggesting the two methods may be used interchangeably.

Conclusions

The ADAP assay is reliable in detecting IA in venous and capillary WB samples with comparable performance to standard RIA and ELISA. These findings open avenues for widespread use of the ADAP assay in future general population screening programs to detect children at risk of developing T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesDiabetes Mellitus, Type 1Islets of LangerhansMass ScreeningPolymerase Chain ReactionHumansChildFemaleMaleAdolescentChild, PreschoolSensitivity and SpecificityReceptor-Like Protein Tyrosine Phosphatases, Class 8Reproducibility of ResultsGlutamate DecarboxylaseEnzyme-Linked Immunosorbent AssayInsulin Antibodies

Substanzen

AutoantibodiesReceptor-Like Protein Tyrosine Phosphatases, Class 8Glutamate DecarboxylaseInsulin Antibodies

Autor:innen und Institutionen

  • The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Enable Biosciences Inc., South San Francisco, CA, USA.
  • Laboratory for Molecular Endocrinology and Diabetes, Felsenstein Medical Research Center, Petach Tikva, Israel.
  • Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Tal Oron, Moshe Phillip, Galia Gat-Yablonski

Förderung

  • Enable Biosciences Inc.
  • Schneider Children’s Medical Center of Israel
  • JDRF

Zitieren

APA

Oron, T., Cortez, F. J., Shtaif, B., Robinson, P. V., Yackobovitch-Gavan, M., Tandel, D., Seftel, D., Phillip, M., Tsai, C. T., & Gat-Yablonski, G. (2024). Detection of Islet Autoantibodies in Whole Blood by Antibody Detection by Agglutination-PCR (ADAP) Technology Is Sensitive and Suitable for General Population Screening Programs. Pediatric Diabetes. https://doi.org/10.1155/2024/4238394

Vancouver

Oron T, Cortez FJ, Shtaif B, Robinson PV, Yackobovitch-Gavan M, Tandel D, et al. Detection of Islet Autoantibodies in Whole Blood by Antibody Detection by Agglutination-PCR (ADAP) Technology Is Sensitive and Suitable for General Population Screening Programs. Pediatric Diabetes. 2024. doi:10.1155/2024/4238394

BibTeX
@article{Oron2024,
  author = {Oron, Tal and Cortez, Felipe de Jesus and Shtaif, Biana and Robinson, Peter V and Yackobovitch-Gavan, Michal and Tandel, Devangkumar and Seftel, David and Phillip, Moshe and Tsai, Cheng-Ting and Gat-Yablonski, Galia},
  title = {Detection of Islet Autoantibodies in Whole Blood by Antibody Detection by Agglutination-PCR (ADAP) Technology Is Sensitive and Suitable for General Population Screening Programs},
  journal = {Pediatric Diabetes},
  year = {2024},
  doi = {10.1155/2024/4238394}
}
Kostenlos starten →